KRAScendo 170
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- NCT05789082 ↗
- Recruiting
- Hoffmann-La Roche
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed
- Arms
- Cohort A - Combination Dose Finding + Dose Expansion · Experimental
- Cohort B - Combination Dose Finding + Dose Expansion · Experimental
- Cohort C - Dose Expansion · Experimental
- Cohort D - Dose Expansion · Experimental
- Enrollment
- 320 (estimated)
- Primary outcomes
- Percentage of Participants with Adverse Events (AEs)
- Sponsor
- Hoffmann-La Roche
- Start
- Jun 20, 2023
- Primary completion
- Jan 29, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT05789082 · updated Oct 6, 2026